BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Ketamine for treatment resistant depression: prospects and pitfall
 s - Dr Rupert McShane\, Dementia Clinical Network Lead - Oxford Academic H
 ealth Science Network\;  Associate Professor of Psychiatry\, Department of
  Psychiatry\, University of Oxford
DTSTART:20171130T123000Z
DTEND:20171130T133000Z
UID:TALK77591@talks.cam.ac.uk
CONTACT:Nicholas Morgan
DESCRIPTION:Ketamine is a potent acute antidepressant in some patients wit
 h otherwise resistant depression.  The time to relapse is variable\, but u
 sually 1-2 weeks.  The scalability of repeated ketamine depends on the rou
 te of administration and on the durability of continued response.  What in
 fluence can concomitant psychotherapy or other glutamateric drugs have on 
 this?  Because it is a licensed drug\, clinical experience is moving faste
 r than research\, which holds risks as well as opportunities.  Based on ou
 r experience of 1000 infusions in 100 patients\, I will illustrate the var
 iety of trajectories shown by daily mood monitoring.  I will suggest that 
 ketamine and related compounds have the potential to be as disruptive to h
 ow we practice psychiatry as ECT was in the 1930s and antipsychotics were 
 in the 1960s.    \n\nThe speaker is Associate Professor of Psychiatry\, De
 partment of Psychiatry\, University of Oxford\, a consultant old age psych
 iatrist\, and lead consultant for ECT at Oxford Health NHS Foundation Trus
 t.\n
LOCATION:Seminar Room\, Herchel Smith Building\, Forvie Site.
END:VEVENT
END:VCALENDAR